Mouse anti-Human CytokeRatin 20 Monoclonal Antibody | anti-KRT20 antibody
Mouse anti CytokeRatin 20
Gene Names
KRT20; K20; CD20; CK20; CK-20; KRT21; MGC35423; KRT20
Reactivity
Human
Applications
Immunohistochemistry, Immunohistochemistry, Immunoprecipitation, Western Blot
Synonyms
CytokeRatin 20; Monoclonal Antibody; Mouse anti CytokeRatin 20; anti-KRT20 antibody
Host
Mouse
Reactivity
Human
Clonality
Monoclonal
Isotype
IgG2a
Clone Number
MKs20-8
Specificity
MKs20-8 may be used as a marker for certain types of carcinomas such as adenocarcinomas of the colon, transitional cell carcinomas of the bladder and Merkel cell tumors of the skin; it may also be used as a sensitive detection of intestinal and gastric foveolar epithelium, urothelial umbrella cells, Merkel cells of epidermis as well as tumors originating therefrom (e.g. primary and metastatic colorectal carcinoma).
Form/Format
Each vial contains 1 ml of culture supernatant of monclonal antibody containing 0.09% sodium azide.
Applicable Applications for anti-KRT20 antibody
Immunohistochemistry (IHC) (frozen), Immunohistochemistry (IHC) (paraffin), Immunoprecipitation (IP), Western Blot (WB)
Application Notes
MKs20-8 is suitable for immunoprecipitation, immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titRation.
Source Note
MKs20-8 is a Mouse monoclonal IgG2a antibody derived by fusion of Mouse myeloma cells with spleen cells from a Balb/c Mouse immunized with electrophoretically purified keRatin K20 from Human intestinal mucosa.
Preparation and Storage
Store at 4 degree C, or in small aliquots at -20 degree C.
Related Product Information for anti-KRT20 antibody
CytokeRatins are a subfamily of intermediate filament proteins and are characterized by a remarkable biochemical diversity, represented in Human epithelial tissues by at least 20 different polypeptides. They range in molecular weight between 40 kDa and 68 kDa and isoelectric pH between 4.9 - 7.8. The individual Human cytokeRatins are numbered 1 to 20. The various epithelia in the Human body usually express cytokeRatins which are not only characteristic of the type of epithelium, but also related to the degree of matuRation or differentiation within an epithelium. CytokeRatin subtype expression patterns are used to an increasing extent in the distinction of different types of epithelial malignancies. The cytokeRatin antibodies are not only of assistance in the differential identification of tumors using immunohistochemistry on tissue sections, but are also a useful tool in cytopathology and flow cytometric assays.
Product Categories/Family for anti-KRT20 antibody
References
Moll, R., Löwe, A., Laufer, J. and Franke, W.W.: CytokeRatin 20 in Human carcinomas: A newhistodiagnostic marker detected by monoclonal antibodies. Am.J.Path. 140, 427-447 (1992). Moll, R., Schiller, D.L. and Franke, W.W.: IdentifiCation of protein IT of the intestinal cytoskeleton as a novel type I cytokeRatin with unusual properties and expression patterns. J.Cell.Biol. 111,567-580 (1990). Moll, R., Zimbelmann, R., Goldschmidt, M.D., Keith, M., Laufer, J., Kasper, M., Koch, P.J., Franke, W.W.: The Human gene encoding cytokeRatin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation 53, 75-93 (1993).
NCBI and Uniprot Product Information
NCBI GI #
NCBI GeneID
Molecular Weight
48,487 Da
NCBI Official Full Name
cytokeratin 20
NCBI Official Synonym Full Names
keratin 20
NCBI Official Symbol
KRT20
NCBI Official Synonym Symbols
K20; CD20; CK20; CK-20; KRT21; MGC35423; KRT20
NCBI Protein Information
keratin, type I cytoskeletal 20; keratin-20; protein IT; cytokeratin 20; cytokeratin-20
UniProt Protein Name
Keratin, type I cytoskeletal 20
Protein Family
UniProt Gene Name
KRT20
UniProt Entry Name
K1C20_HUMAN
NCBI Description
The protein encoded by this gene is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. This cytokeratin is a major cellular protein of mature enterocytes and goblet cells and is specifically expressed in the gastric and intestinal mucosa. The type I cytokeratin genes are clustered in a region of chromosome 17q12-q21. [provided by RefSeq]
Uniprot Description
K20: a type I cytoskeletal keratin. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. There are two types of cytoskeletal and microfibrillar keratin: type I (acidic; 40-55 kDa) [K9 to K20] and type II (neutral to basic; 56-70 kDa) [K1 to K8]. Both a basic and an acidic keratin are required for filament assembly.
Protein type: Cytoskeletal
Chromosomal Location of Human Ortholog: 17q21.2
Cellular Component: cytoplasm; intermediate filament
Molecular Function: protein binding; structural constituent of cytoskeleton
Biological Process: regulation of protein secretion; apoptosis; cellular response to stress; intermediate filament organization
Research Articles on KRT20
1. MMP-11 and CK-20 are probable prognostic markers whose expression reflects the stages of tumor differentiation and LNM of breast cancer.
2. CK20 expression is associated with the progression of breast cancer.
3. The expression level of CK20 mRNA in the peripheral blood in patients with gastric cancer declines after postoperative adjuvant chemotherapy.
4. Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)
5. Chromogranin A, synaptophysin and CK 20 were not expressed in any basal cell carcinoma
6. Data suggest that CD10 and CK20 may be used for the differential diagnosis of MCN and IPMN-BD.
7. CK20 and CEA are significantly more frequently detected in colon cancer patients than in healthy controls and can serve as markers.
8. It can be helpful in cases with metastatic rectal carcinoma, especially those with CK7+/CK20+ or CK20-/CK7- immunophenotype.
9. CK20 and MUC2 mRNA were quantitated in 52 normal lymph nodes from 12 patients undergoing surgery for benign bowel diseases and in 144 primary colon tumors.
10. CK20 and CEA are expressed in non-macroscopically involved lymph nodes of colorectal cancer.
11. KRT20 is directly regulated by CDX1, suggesting a role for CDX1 in maintaining differentiation in intestinal epithelial cells
12. Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer.
13. GPC3 is frequently expressed in noncutaneous small cell neuroendocrine carcinoma of various origins, in particular in Merkel cell carcinoma, which, in combination with CK20
14. Micrometastases of gastric cancer can be detected in circulating peripheral blood using quantitative real-time RT-PCR. CK19 is a better marker than CK18, CK20 and CEA.
15. The diagnostic efficacy of urinary CD44 and cytokeratin 20 (CK20) mRNA in comparison with voided urine cytology (VUC) for the detection of bladder cancer, was evaluated.
16. These results indicate that the epithelial barrier of the human adenoid is stably maintained by expression of tight junction proteins in the epithelium including Ck20-positive M-like cells.
17. CK20-positive cells in lymph nodes and circulating mRNA in blood are detected in patients with colorectal neoplasms.
18. The combined expression of CK7 and CK20 has a low specificity in the distinction between esophageal and cardiac (stomach) adenocarcinomas.
19. Possible relationship between expression of CK7 and CK20 and neoplastic development of colorectal mucosa in patients with ulcerative colitis.
20. Positive CK20 RT-PCR, depth of tumor invasion, lymph node status, metastasis and microvessel density are significantly correlated with vascular invasion.
2. CK20 expression is associated with the progression of breast cancer.
3. The expression level of CK20 mRNA in the peripheral blood in patients with gastric cancer declines after postoperative adjuvant chemotherapy.
4. Observational study and genome-wide association study of gene-disease association. (HuGE Navigator)
5. Chromogranin A, synaptophysin and CK 20 were not expressed in any basal cell carcinoma
6. Data suggest that CD10 and CK20 may be used for the differential diagnosis of MCN and IPMN-BD.
7. CK20 and CEA are significantly more frequently detected in colon cancer patients than in healthy controls and can serve as markers.
8. It can be helpful in cases with metastatic rectal carcinoma, especially those with CK7+/CK20+ or CK20-/CK7- immunophenotype.
9. CK20 and MUC2 mRNA were quantitated in 52 normal lymph nodes from 12 patients undergoing surgery for benign bowel diseases and in 144 primary colon tumors.
10. CK20 and CEA are expressed in non-macroscopically involved lymph nodes of colorectal cancer.
11. KRT20 is directly regulated by CDX1, suggesting a role for CDX1 in maintaining differentiation in intestinal epithelial cells
12. Loss of CDX2 and CK20 is more frequently encountered in mismatch repair-deficient colorectal cancer.
13. GPC3 is frequently expressed in noncutaneous small cell neuroendocrine carcinoma of various origins, in particular in Merkel cell carcinoma, which, in combination with CK20
14. Micrometastases of gastric cancer can be detected in circulating peripheral blood using quantitative real-time RT-PCR. CK19 is a better marker than CK18, CK20 and CEA.
15. The diagnostic efficacy of urinary CD44 and cytokeratin 20 (CK20) mRNA in comparison with voided urine cytology (VUC) for the detection of bladder cancer, was evaluated.
16. These results indicate that the epithelial barrier of the human adenoid is stably maintained by expression of tight junction proteins in the epithelium including Ck20-positive M-like cells.
17. CK20-positive cells in lymph nodes and circulating mRNA in blood are detected in patients with colorectal neoplasms.
18. The combined expression of CK7 and CK20 has a low specificity in the distinction between esophageal and cardiac (stomach) adenocarcinomas.
19. Possible relationship between expression of CK7 and CK20 and neoplastic development of colorectal mucosa in patients with ulcerative colitis.
20. Positive CK20 RT-PCR, depth of tumor invasion, lymph node status, metastasis and microvessel density are significantly correlated with vascular invasion.
Similar Products
Product Notes
The KRT20 krt20 (Catalog #AAA570010) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Mouse anti CytokeRatin 20 reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's CytokeRatin 20 can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC) (frozen), Immunohistochemistry (IHC) (paraffin), Immunoprecipitation (IP), Western Blot (WB). MKs20-8 is suitable for immunoprecipitation, immunoblotting and immunohistochemistry on frozen and paraffin-embedded tissues. Optimal antibody dilution should be determined by titRation. Researchers should empirically determine the suitability of the KRT20 krt20 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "CytokeRatin 20, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
